Evaluation of oral administration of firocoxib for the management of musculoskeletal pain and lameness associated with osteoarthritis in horses.

This research explores the impact of firocoxib, an anti-inflammatory drug, on managing joint pain and lameness in horses diagnosed with osteoarthritis. Over two weeks, the horses showed significant improvement with minimal adverse effects, making it a potentially safe treatment option for this condition.

Study Overview

• The study aimed to assess the impact of firocoxib on horses suffering from osteoarthritis-related lameness and joint pain.
• It involved client-owned horses that exhibited signs of lameness and joint pain related to osteoarthritis.
• Firocoxib was administered to the horses orally (through a paste form) daily for 14 days, with the dosage being at 0.1 mg/kg.

Selection and Evaluation

• Out of 429 proposed subjects from 80 sites across 25 states, 390 horses met the necessary criteria for the analysis.
• The most represented breeds were the Quarter Horse and Thoroughbred, making up half of the study population.
• Osteoarthritis-related pain or lameness was diagnosed in either a single joint (in about 50.5% of the horses) or multiple joints (in about 49.5% of the horses). For those diagnosed with a single joint, the tarsus was the most frequently affected.
• Data collected over the research period was thoroughly assessed. Assessments were carried out on the 0th day (baseline), the 7th day, and the 14th day.

Results and Conclusions

• By day 14 of treatment, approximately 80% of the 390 horses showed marked improvement.
• A significant number of horses, rated by investigators (78.7%) and owners or handlers (81.0%), were considered improved by the end of the study.
• Firocoxib paste use substantially improved lameness scores from the baseline values. The improvement was most notable within the first seven days and continued, albeit slower, until the 14th day of treatment.
• Given these results, the study concluded that the use of firocoxib significantly improved lameness scores with few adverse effects reported. It suggests that firocoxib can serve as a safe NSAID specific to cyclooxygenase-2 in treating musculoskeletal pain and lameness associated with osteoarthritis in horses.